Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States. The company provides nanoforming technologies, formulation, and analytical services, including controlled expansion of supercritical solutions technology that enables the creation of active pharmaceutical ingredients (API) nanoparticles directly from solution; biological nanoforming technology; and dosage forms of Nanoparticles. It also offers STARMAP, an AI platform predicts the performance of your molecule in Nanoform's technology. The company was founded in 2008 and is headquartered in Helsinki, Finland.…
Suomalainen Nanoform teki sopimuksen merkittävän lääkevalmistajan kanssa
Nanoform Finland (HEL: NANOFH) is listed on Nasdaq Helsinki, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 108 employees.
The shares were at 0.7080 EUR on 20 November 2026, down 36.7% over 52 weeks. Its 52-week range is 0.3770 EUR to 1.232 EUR: the price is 42.5% below the high and 87.8% above the low.
Its market capitalisation is 60.71M EUR.
Nanoform Finland reports return on equity of -41.8%, an operating margin of -296.3% and revenue up 16.2% year over year.
It holds more cash than debt, a net cash position of 12.60M EUR. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 2.125 EUR is 200.1% above the current price. The next earnings report is expected on 25 February 2027.